Targeting PI3Kß alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss.

Owusu-Brackett, Nicci; Zhao, Ming; Akcakanat, Argun; Evans, Kurt W; Yuca, Erkan; Dumbrava, Ecaterina Ileana; Janku, Filip; Meric-Bernstam, Funda

Owusu-Brackett, Nicci; Zhao, Ming; Akcakanat, Argun; Evans, Kurt W; Yuca, Erkan; Dumbrava, Ecaterina Ileana; Janku, Filip; Meric-Bernstam, Funda.

Afiliación

Owusu-Brackett N; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Zhao M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Akcakanat A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Evans KW; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yuca E; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Dumbrava EI; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Meric-Bernstam F; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Oncotarget ; 11(11): 969-981, 2020 Mar 17.

Article en En | MEDLINE | ID: mdl-32215185

Palabras clave

AZD8186; PI3Kß; PTEN loss; chemotherapy; immunotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google